September 20, 2023
December 27, 2023
September 20, 2023
Oklahoma's film and tv industry continues to grow. And now Prairie Surf Studios is expanding it's services with the launch of Prairie Surf Creative; the goal is to amplify Oklahoma's creative voices.
Read More
October 23, 2023
For two decades, Rachel Cannon lived a life in Los Angeles that many would envy. But in 2020, she decided to return to her native Oklahoma with the idea of traveling back and forth for work, using her home state as a hub. Then, plot twist on top of plot twist, she hit upon a crazy idea: Why not turn Oklahoma City’s convention center, which was being replaced by a new facility, into a full-service film and TV production complex?
Read More
October 17, 2023
Nucleus RadioPharma, the world’s first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals has announced an oversubscribed $56 million Series A funding round led by Eclipse and GE HealthCare with participation from Echo Global, Fox Chase Cancer Center, Granger Management, Mayo Clinic, Mercy Health, and University of Missouri. With this round of funding, Nucleus RadioPharma will establish multiple new manufacturing facilities around the country, including Rochester, Minnesota, near Mayo Clinic, and build novel technology for the development, manufacturing, and distribution of radiopharmaceuticals.
Read More
June 6, 2023
The costs, in both money and time, behind building, operating, and maintaining a safety testing facility can be a distraction that prevents therapeutic manufacturers from their mission of bringing safe, effective treatments to patients in a timely manner. That’s why Wheeler Bio chose to partner with Charles River and the RightSource℠ team. It’s more than just outsourcing for your safety testing – it’s a GMP lab-in-a-box that provides a scalable, easily reproducible alternative to the current industry approach to biopharmaceutical testing.
Read More
October 5, 2023
By partnering uniquely with venture capital, Wheeler helps to ease the translational process from discovery to clinic for clients in biologics innovation. Founded by Dr. Jesse McCool, Christian Kanady of Echo, and Errik Anderson of Alloy Therapeutics and 82VS in 2021, the first-in-class CDMO was designed to provide accelerative development services to biotech startups and emerging biopharma innovators at a fair price.
Read More
October 5, 2023
Wheeler Bio, a contract development and manufacturing organization, or CDMO, for next-generation protein therapeutics, will begin production for customers next month in the 35,000-square-foot Ziggurat building in downtown Oklahoma City. CEO Jesse McCool launched the company close to three years ago with the intention of filling a gap that exists between drug discovery and scale-up manufacturing of small-molecule biologic drugs used for cancer and autoimmune conditions.
Read More
July 25, 2023
Local biotech startup Wheeler Bio is poised to start manufacturing batches of molecules this fall, after settling into what it calls the facility of the future.
Read More
April 13, 2023
Wheeler Bio, a CDMO specializing in therapeutic antibodies, has closed its Series A funding round, co-led by Charles River Laboratories and Echo. The firm's Portable CMC is an open-source middleware that enhances the gene-to-IND supply chain, delivering speed, efficiency, predictability, and freedom to operate. The firm intends to complete a 500L scale CGMP cell banking and drug substance manufacturing facility in Oklahoma City, with the first batches of production set to commence in Q3 2023. The new facility will utilize integrated tools and technologies like Solentim, Ambr Microbioreactors, and DynaDrive Single-Use Bioreactors.
Read More
April 5, 2023
Deka Biosciences has announced the dosing of the first subject in a Phase 1 clinical trial of DK210 (EGFR), a novel cytokine therapy for cancer and inflammatory diseases. The trial aims to evaluate the safety, potential efficacy, and biomarker responses of the therapy in patients with advanced solid cancer(s) expressing epidermal growth factor receptors. DK210 (EGFR) is the first of several DiakinesTM developed by Deka, which involves coupling two cytokines onto a single targeting system for enhanced precision and efficacy. The self-administered treatment is expected to provide patients with greater comfort and convenience.
Read More
January 30, 2023
Deka Biosciences ("Deka"), a biotech company focused on developing novel cytokine therapies to treat cancer and inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the investigational new drug (IND) application for DK210 (EGFR) and concluded that Deka may proceed with a Phase 1 clinical trial in the United States.
Read More